10x Genomics, Inc. (NASDAQ: TXG)
Key Finding: 10x Genomics (TXG) is a leading provider of single-cell and spatial biology tools that experienced a sharp stock rebound in mid-2026 driven by multiple analyst price target upgrades and new product momentum, with shares rising over 160% year-to-date as of early July 2026.
Company Overview
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. Its platforms enable researchers to study genomics, transcriptomics, epigenomics, and spatial biology in unprecedented detail.
- Headquarters: Pleasanton, California
- Founded: 2012
- CEO: Serge Saxonov (co-founder)
- Employees: Approximately 1,178
- Website: 10xgenomics.com | Investor Relations: investors.10xgenomics.com
- Core Platforms: Chromium (single-cell), Visium/Xenium (spatial), new Atera (in situ spatial biology, shipments expected H2 2026)
The company serves academic institutions, pharmaceutical/biotech firms, and government research organizations globally.
Company History
- 2012: Founded as 10X Technologies by Serge Saxonov, Ben Hindson, and Kevin Ness.
- 2014: Renamed 10x Genomics, Inc.
- 2019: Initial public offering on September 12, raising approximately $370 million.
- Post-IPO: Expanded product portfolio with spatial biology solutions (Visium, Xenium) and continued innovation in single-cell technologies.
- 2026: Acquisition of Proteintech Genomics (June); launch of Atera platform; partnership with Bioptimus for STELA initiative.
The company has grown from a startup focused on single-cell tech to a leader in high-resolution biological analysis tools, with significant R&D investment driving platform expansions.
Recent News (2025–2026)
- Q1 2026 Earnings (May 2026): Revenue $150.8 million (–3% YoY; +9% excluding 2025 one-time patent settlement). Gross margin 70%. Net loss narrowed to $13.5 million. FY2026 revenue guidance reaffirmed at $600–$625 million. Announced Atera launch.
- June 2026: Acquired Proteintech Genomics to expand multiomics capabilities. Multiple analyst upgrades (Barclays to $40, Citi to $45, others raised targets significantly).
- July 2026: Stock surged on upgrades and momentum; hit 52-week highs near $43.
- Other: Collaboration with Cleveland Clinic on bladder cancer research using single-cell/spatial tech.
Sources include company press releases and financial reports via investors site and aggregators like StockTitan.
News is time-sensitive; verify latest via official channels as events evolve rapidly.
Stock Performance
Recent Price (as of ~July 9–10, 2026): Approximately $41–$43 (intraday highs near $43.10; closed around $37.47 on July 8 before surge).
Key Metrics
| Metric | Value | Notes |
|---|
| 52-Week Range | $11.16 – $43.10 | Significant volatility and recent recovery |
| YTD Return (2026) | +~160–164% | Strong rebound from early-year levels (~$16.31) |
| 1-Year Return | +~256% | Outperformed broader market substantially |
| Market Cap | ~$4.8B – $5.5B | Mid-cap classification |
| All-Time High | $202.37 (April 26, 2021) | Peak during biotech boom |
Annual Performance Summary (Approximate Closing Prices)
| Year | Year-End Close (approx.) | Annual Change |
|---|
| 2021 | $148.96 | +5.20% |
| 2022 | $36.44 | –75.54% |
| 2023 | $55.96 | +53.57% |
| 2024 | $14.36 | –74.34% |
| 2025 | $16.31 | +13.58% |
| 2026 (YTD through early July) | ~$37–43 | +160%+ |
Data compiled from Yahoo Finance, Macrotrends, and company investor pages. No dividends paid (growth-stage biotech typical).
Links for More Information
Data Limitations & Assumptions: All stock prices, financials, and news are snapshots based on publicly available data as of searches conducted around July 9–10, 2026. Stock markets fluctuate continuously—prices shown are not real-time. Financial results exclude forward-looking guidance risks. Analyst ratings/targets are opinions and subject to change. No investment advice is provided; consult professionals and primary sources for current data.
Distinction: Facts are directly from company reports and financial databases. Interpretations (e.g., "sharp rebound driven by upgrades") are analyst/market observations. Uncertainties include future earnings, product adoption of Atera, and macroeconomic impacts on biotech spending.